TOVX
What one share of Theriva Biologics holds
Pharmaceutical Preparations
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L.
Theriva Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.42 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.41 |
| Cash and investments | $0.25 |
| Debt | $0.04 |
| Book value | $0.27 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$72.26 | $1.51 | −$75.48 | — | — |
| 2017 | — | −$1,557 | $14.92 | −$1,436 | — | — |
| 2018 | — | −$1,014 | $0.28 | −$693.39 | — | — |
| 2019 | — | −$244.49 | $0.00 | −$210.99 | — | — |
| 2020 | — | −$165.12 | $0.12 | −$160.13 | — | — |
| 2021 | — | −$47.57 | $0.03 | −$26.47 | — | — |
| 2022 | — | −$32.66 | $0.19 | −$31.31 | — | — |
| 2023 | — | −$28.48 | $0.31 | −$29.80 | — | — |
| 2024 | — | −$19.03 | $0.00 | −$12.56 | — | — |
| 2025 | — | −$2.08 | $0.00 | −$1.38 | — | $0.43 |